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Opinion
Type 1 Interferons and Antiviral CD8 T-Cell Responses
Raymond M. Welsh*, Kapil Bahl¤, Heather D. Marshall¤, Stina L. Urban
Department of Pathology and Program in Immunology and Virology, University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
Type 1 interferons (IFNs) were the first
cytokines discovered and include IFNb,
.ten forms of IFNa, and several other
related molecules that all bind to the same
type 1 IFN receptor (IFN1R). Type 1 IFNs
are commonly referred to as ‘‘viral’’ IFNs
because they can be induced directly by
virus infections, in contrast to ‘‘immune’’
IFN, or IFNc, which is synthesized after
receptor engagement of T cells and
natural killer (NK) cells during immune
responses. Type 1 IFNs get induced by
viral nucleic acids and proteins acting on
cellular signaling molecules such as Toll-
like receptors and RNA helicases, which,
in turn, release transcription factors into
the nucleus. Mice lacking IFN1R appear
normal in a pathogen-free environment
but are extraordinarily susceptible to virus
infections [1]. This susceptibility is partial-
ly due to IFN-regulated genes that sup-
press viral replication, but type 1 IFNs also
have many immunoregulatory properties
that could also affect host susceptibility to
infection.
Indications of the immunoregulatory
roles of type 1 IFN came in the 1970s
with observations that IFN upregulated
the expression of class 1 MHC antigens
[2], enhanced histamine secretion by
triggered Mast cells [3], and cytolytically
activated NK cells [4–6]. Several studies
showed that addition of IFN to mixed
lymphocyte cultures could enhance or
inhibit T-cell proliferation, depending on
the dose [7]. IFN was then shown to elicit
NK cell proliferation in vivo by a mech-
anism involving the induction of IL-15, a
growth factor for NK cells [8,9]; a similar
phenomenon of IFN and IL-15 was later
shown for the division of memory T cells
[10]. In the past decade a substantial
number of new insights have developed in
regards to how IFN can directly or
indirectly affect T-cell responses to viral
infections. IFN can affect T-cell responses
by acting on the antigen-presenting cells
(APCs), by acting on the T cells, or by
inducing other cytokines and chemokines
that regulate T-cell responses. Of note is
that the phenotype of the T cells and the
timing of IFN exposure are of essence, as
IFN can inhibit proliferation or induce
apoptosis under some circumstances yet be
dramatically stimulatory under other con-
ditions. Depending on their activation
status, T cells can change their expression
levels of IFN1R and their expression of
signaling molecules downstream from the
IFN1R.
Mechanisms of IFN Signaling
and Gene Activation
All type 1 IFNs bind to a receptor of
two chains, IFNaR1, which is constitu-
tively bound to tyrosine kinase 2 (TYK2),
and IFNaR2, which is constitutively
bound to Janus kinase 1 (JAK1). Ligand
binding induces dimerization of both
receptor chains and the phosphorylation
of TYK2, JAK1, and the intracellular
tyrosine residues of each IFN1R chain
[11–13]. The transphosphorylation of
both chains by these kinases results in
activation of signal transducers and acti-
vators of transcription (STATs) 1 and 2.
These form complexes that are translocat-
ed into the nucleus and activate the
transcription of a wide variety of genes
regulated by IFN-stimulated response
elements (ISRE) [14,15]. Type 1 IFNs
can limit CD8 T-cell expansion when
acting through STAT1, but they can also
activate other STATs and promote T-cell
expansion when, for example, acting
through STAT4 [16,17]. Type 1 IFNs
can also activate STAT 3 and 5, which
can mediate antiapoptotic and promito-
genic effects in T cells that escape the
antimitotic effects of IFN by downregulat-
ing STAT1 after activation [13,18].
Type 1 IFN plays a major role in the
CD8 T-cell response to viral infection, and
its effects are on both the APCs (Figure 1A
and 1B) and on the T cells (Figure 1D). T
cells that are exposed to their cognate
peptide antigen presented in the context of
MHC (pMHC) on APC-like dendritic cells
(DCs) get costimulated through receptors
such as CD28 and CD40 ligand and
undergo a differentiation program associ-
ated with several cycles of division, the
expression of the transcription factors t-bet
and eomesodermin, followed by the ac-
quisition of effector functions (Figure 1D).
These effector functions include cytotox-
icity associated with the synthesis of the
cytolytic proteins like perforin and the
ability to secrete antiviral cytokines such as
IFNc [19–22]. Type 1 IFN upregulates
expression of both MHC and costimula-
tory molecules and in so doing can greatly
affect the initiation of these T-cell respons-
es (Figure 1A and 1D) [23]. Overall, there
is dramatic upregulation of MHC even in
nonprofessional APC throughout the host
during the course of a viral infection [24].
Costimulation of CD8 T Cells by
Type 1 IFN
Type 1 IFN can provide a major
costimulatory effect in its own right by
binding to the IFN1R on CD8 T cells and
greatly augmenting their proliferation
(Figure 1D) [17,25,26]. IFNc, if present,
can elicit a similar effect [27]; this was
demonstrated in IFN1R bone marrow
chimeric mice infected with lymphocytic
choriomeningitis virus (LCMV), where the
IFN1R+ CD8 cells greatly outgrew the
IFN1R- CD8 T cells. Interestingly, this
effect was much less profound with
vaccinia virus, which is a poor type 1
IFN inducer. Vaccinia virus, however, is a
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Figure 1. Effect of type 1 IFN on T-cell activation, proliferation, and apoptosis. This schematic shows the effects of type 1 IFN on antiviral
CD8 T-cell responses. (A) A virus infects an APC and induces IFN, which upregulates MHC and costimulatory molecules. (B) Activated APCs migrate
into the spleen and lymph nodes to present viral pMHC to T cells. (C) IFN promotes apoptosis of preexisting memory T cells, which are rapidly
phagocytosed by CD8a+ DCs. (D) IFN directly promotes the proliferation of antigen (Ag)-specific CD8 T cells at the beginning of the response. (E) IFN
indirectly enables late comer Ag-specific T cells to become immediate effectors, but directly inhibits proliferation. (F) After synchronized contraction,
the host is left with a new population of memory T cells and a loss of preexisting memory cells.
doi:10.1371/journal.ppat.1002352.g001
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good inducer of IL-12, and IL-12 seems to
play a compensatory stimulatory role for T
cells in that infection [28]. IFN 1 has
potent growth-inhibitory and apoptotic
properties, so one might be surprised
about this direct augmentation of prolifer-
ation. However, as mentioned above, IFN
1–induced growth inhibition is in part
mediated through STAT1, but antigen-
activated CD8 T cells during LCMV
infection downregulate STAT1 and get
released from that block [29]. Mice
lacking STAT1 experience a putative
‘‘nonspecific’’ proliferation of their CD8
T cells, so it is speculated that IFN 1
signaling through STAT1 may retard
nonspecific proliferation and allow the
antigen-specific T cells to develop. The
action of IFN 1 through other STAT
molecules can induce antiapoptotic effects
and augment the proliferation of T cells.
Altered T-Cell Differentiation
and Proliferation Caused by
Out-of-Sequence Signaling
The timing of IFN exposure can greatly
affect the T-cell differentiation pathway
and the magnitude of the T-cell response.
It is well established that exposure to IFNc
promotes the differentiation of CD4 T
cells into IFNc-secreting Th1 cells [30,31],
but here we are talking about a timing-
dependent exposure of CD8 T cells to type
1 IFN. Exposure of naı¨ve CD8 T cells to
APC and IFN before exposure to cognate
antigen upregulates the T-cell expression
of eomesodermin and sensitizes T cells to
enter an altered differentiation pathway on
encounter with cognate antigen (Figure 1E)
[32]. Instead of undergoing several divi-
sions before exerting effector functions,
these sensitized CD8 T cells retain a naı¨ve
antigenic phenotype but act like memory
cells and develop effector-cell properties
associated with cytokine production and
cytolytic activity within 2–4 h. This is not
due to a direct effect of IFN on the T cells,
as it occurs even if T cells lack IFN1R. It is
more likely due to IFN acting on the
APCs, which need to express the restrict-
ing MHC molecule for the cognate
peptide to sensitize the T cells to respond
differently to the cognate peptide.
We propose that the enhanced expres-
sion of MHC- presenting self-peptide
provides a low level stimulus to naı¨ve T
cells, enabling them to retain a naı¨ve T-
cell antigenic phenotype yet produce
transcription factors that allow them to
respond to cognate peptide like a memory
T cell.
A common phenomenon occurring
during the course of a viral infection is a
transient immune deficiency whereby T
cells respond poorly to T-cell mitogens in
vitro and to challenge with nonviral
antigens in vivo [33]; this is, in fact, why
one should not get vaccinated during
illness. Several phenomena could account
for this deficiency, including growth of
virus in T cells, impaired antigen presen-
tation, competition for T-cell growth
factors, and induction of activation-in-
duced cell death in a Fas ligand-rich
environment. However, we have recently
shown that type 1 IFN itself may account
for much of this immune suppression, if
the T cells are exposed to the IFN before
cognate antigen encounter (Figure 1E)
[34]. Prior exposure to IFN before cognate
antigen stimulus impairs the proliferation
of T cells after the antigen stimulus, even
in the presence of IFN acting as a
costimulatory factor, and the inhibition
of proliferation in this case requires
IFN1R on the T cells. The molecular
mechanism for this IFN-induced impair-
ment of proliferation is unknown, but this
is reminiscent of earlier work showing that
NK cells become hyporesponsive to IFN-
mediated activation after having received
a prior IFN stimulus [35,36].
Therefore, T cells that receive an IFN
stimulus prior to cognate antigen exposure
become sensitized to immediately become
effector cells by an indirect IFN-dependent
mechanism; but they undergo reduced
proliferation by a direct IFN-dependent
mechanism. Together these mechanisms
may limit de novo T-cell responses in the
midst of a viral infection and may aid in
the synchronization of the contraction
phase of the immune response, because
T cells recruited late into the antiviral
response would undergo reduced clonal
expansion.
IFN-Induced Apoptosis and
Attrition of Memory T Cells
IFN-inducing viral infections have a
deleterious effect on memory CD8 and
CD4 T cells specific to other antigens. We
show here that memory-phenotype CD8
T cells express moderately higher levels of
IFN1R than do naı¨ve T cells (Figure 2),
and it is not unusual for 50%–80% of the
memory CD8 T cells to undergo an IFN-
induced apoptosis early during infection
(Figure 1C) [37–40]. Some naı¨ve cells also
die in the earlier stages of infection, but to
a much lower extent. This apoptosis is
associated with elevated caspases, annexin
V-staining, and DNA fragmentation and is
at least partially dependent on Bim, known
to be a proapoptotic molecule induced by
type 1 IFN [39,41]. Of note is that type 1
IFN inducers drive a substantial increase
in the number of the highly phagocytic
CD8a+, CD11c+ DC population into the
spleen of mice (Figure 1B and 1C) [39].
These DC assimilate apoptotic cells and
become reactive with Annexin V in the
process, making it difficult to quantify
apoptotic T cells directly ex vivo and easy
to confuse CD8+ T cells with CD8+ DC.
The IFN-induced apoptosis of memory T
cells can occur in the presence of cognate
antigen [38], leading one to question why
such a mechanism should exist, as one
might want to rapidly recruit antigen-
specific memory cells into an immune
response. One possibility is that this loss in
memory cells is well tolerated because of
their initial high frequencies and that it
creates room for new T-cell responses to
vigorously develop. It has been known for
decades that partial depletion of lympho-
cyte populations can augment new T-cell
responses [42,43]. Further, should these
memory T cells cross-react with another
pathogen, a reduction in their number
may prevent them from overzealously
dominating the T-cell response to the
cross-reactive epitope [38]. This IFN-
induced loss in memory T cells at the
beginning of infections would allow for a
more diverse and presumably more effec-
tive T-cell response to that pathogen.
Memory T cells may often be present in
clonal excess such that the host can reduce
their numbers without deleterious effects.
However, a series of infections with
heterologous pathogens has been shown
to reduce memory T-cell numbers to levels
that compromise the host’s resistance to
infections [44,45].
Conclusion: Sequence of Type 1
IFN–Induced Events during a
Viral Infection
We now can envisage the series of type
1 IFN–induced events that control CD8
T-cell responses to viral infections
(Figure 1). A virus will infect a host and
possibly a DC and induce IFN that
upregulates MHC and costimulatory mol-
ecules, and then the activated DC mi-
grates into the spleen and lymph nodes
(Figure 1A and 1B). IFN induces the
apoptosis of many of the memory cells
and some of the naı¨ve cells, making room
in the immune system to drive a strong T-
cell response (Figure 1C). The antigen-
specific T cells downregulate the antipro-
liferative STAT1, allowing IFN signals to
go through other STAT molecules that
inhibit apoptosis and promote prolifera-
tion (Figure 1D). Type 1 IFN acts as a
strong costimulatory factor driving T-cell
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expansion. Late comer T cells in the
immune response will be indirectly sensi-
tized by IFN to immediately become
effector cells but at the expense of
proliferation, which is suppressed by direct
IFN signaling (Figure 1E). After the virus is
cleared, the T-cell response synchronously
contracts, leaving the host with a pool of
new memory cells and a loss of previously
existing ones (Figure 1F).
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